Advertisement

Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer

Published:October 14, 2022DOI:https://doi.org/10.1016/j.ejca.2022.09.014

      Highlights

      • Nivolumab induced a durable response in subset of patients with biliary cancer.
      • Clinical information and tumour samples were collected for potential biomarkers.
      • Asian, PD-L1 expression and CD8 T cell infiltration can be potential biomarkers.
      • A six-gene predictive model was constructed to predict nivolumab response.

      Abstract

      Background

      Our previous phase II study demonstrated that nivolumab provides modest but durable clinical efficacy in patients with refractory biliary tract cancer, suggesting the significant clinical benefit of nivolumab in selected patients and the necessity of predictive biomarkers. We evaluated clinicopathological characteristics and tumour microenvironment of the patients who were enrolled the trial to identify potential biomarkers.

      Methods

      Baseline clinicopathological characteristics and pretreatment tumour samples were collected. The obtained tumour samples were assessed for whole exome sequencing, RNA sequencing and immunohistochemistry. Their correlations with clinical outcome were analysed.

      Results

      Pretreatment tumour evaluation revealed PD-L1 expression on tumour, CD8 T cell infiltration and high ratio of CD8 T cell/regulatory T cell in tumour microenvironment were significantly associated with prolonged progression-free survival (PFS), while PD-1 expression on lymphocytes and CD68 macrophages infiltration in tumour microenvironment had no predictive role. Asian patients (N = 3) had improved PFS and disease control rate compared with non-Asian (N = 54). A six-gene predictive model was constructed by evaluation of total 23,550 candidate genes from RNA sequencing of baseline tumour samples using LASSO-Cox regression analysis, and high score of the six-gene prediction model was associated with prolonged PFS.

      Conclusion

      This study suggests that PD-L1 expression on tumour, CD8 T cell infiltration and high ratio of CD8/regulatory T cells and six-gene expression profile in tumour microenvironment may be potential predictive biomarkers of nivolumab in biliary tract cancers. Further studies are needed to confirm these findings.

      Keywords

      Abbreviations:

      BTC (biliary tract cancer), CI (confidence interval), HR (hazard ratio), OS (overall survival), PFS (progression-free survival), PR (partial response), RNAseq (RNA sequencing), SD (stable disease), Treg (regulatory T cell), WES (whole exome sequencing)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kim R.D.
        • Chung V.
        • Alese O.B.
        • El-Rayes B.F.
        • Li D.
        • Al-Toubah T.E.
        • et al.
        A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer.
        JAMA Oncol. 2020; 6: 888-894
        • Le D.T.
        • Durham J.N.
        • Smith K.N.
        • Wang H.
        • Bartlett B.R.
        • Aulakh L.K.
        • et al.
        Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
        Science. 2017; 357: 409-413
        • Winkelmann R.
        • Schneider M.
        • Hartmann S.
        • Schnitzbauer A.A.
        • Zeuzem S.
        • Peveling-Oberhag J.
        • et al.
        Microsatellite instability occurs rarely in patients with cholangiocarcinoma: a retrospective study from a German Tertiary Care Hospital.
        Int J Mol Sci. 2018; 19
        • Shao C.
        • Li G.
        • Huang L.
        • Pruitt S.
        • Castellanos E.
        • Frampton G.
        • et al.
        Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors.
        JAMA Netw Open. 2020; 3e2025109
        • Ott P.A.
        • Bang Y.J.
        • Piha-Paul S.A.
        • Razak A.R.A.
        • Bennouna J.
        • Soria J.C.
        • et al.
        T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028.
        J Clin Oncol. 2019; 37: 318-327
        • Ioka T.
        • Ueno M.
        • Oh D.
        • Fujiwara Y.
        • Chen J.
        • Doki Y.
        • et al.
        Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
        Gastrointestinal Cancer Symposium 2019. 2019 (San Francisco, CA)
        • Ueno M.
        • Chung H.C.
        • Nagrial A.
        • Marabelle A.
        • Kelley R.K.
        • Xu L.
        • et al.
        Pembrolizumab for advanced biliary adenocarcinoma: results from the multicohort, phase 2 KEYNOTE-158 study.
        ESMO 2018 Congress. 2018 (Munich, Germany)
        • Bang Y.J.
        • Ueno M.
        • Malka D.
        • Chung H.C.
        • Nagrial A.
        • Kelley R.K.
        • et al.
        Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.
        2019 ASCO Annual Meeting. 2019 (San Francisco, CA)
        • Oh D.Y.
        • He A.R.
        • Qin S.
        • Chen L.
        • Okusaka T.
        • Vogel A.
        • et al.
        A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.
        2022 ASCO Gastrointestinal Cancers Symposium. 2021 (San Francisco)
        • Peng L.
        • Qin B.D.
        • Xiao K.
        • Xu S.
        • Yang J.S.
        • Zang Y.S.
        • et al.
        A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy.
        Oncoimmunology. 2020; 91781333
        • Cao J.
        • Hu J.
        • Liu S.
        • Meric-Bernstam F.
        • Abdel-Wahab R.
        • Xu J.
        • et al.
        Intrahepatic cholangiocarcinoma: genomic heterogeneity between Eastern and Western patients.
        JCO Precis Oncol. 2020; 4
        • Wang C.
        • Sandhu J.
        • Ouyang C.
        • Ye J.
        • Lee P.P.
        • Fakih M.
        Clinical response to immunotherapy targeting programmed cell death receptor 1/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases.
        JAMA Netw Open. 2021; 4e2118416
        • Yu J.
        • Green M.D.
        • Li S.
        • Sun Y.
        • Journey S.N.
        • Choi J.E.
        • et al.
        Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.
        Nat Med. 2021; 27: 152-164
        • Bai R.
        • Lv Z.
        • Xu D.
        • Cui J.
        Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors.
        Biomark Res. 2020; 8: 34
        • Piha-Paul S.A.
        • Oh D.Y.
        • Ueno M.
        • Malka D.
        • Chung H.C.
        • Nagrial A.
        • et al.
        Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies.
        Int J Cancer. 2020; 147: 2190-2198
        • Goeppert B.
        • Frauenschuh L.
        • Zucknick M.
        • Stenzinger A.
        • Andrulis M.
        • Klauschen F.
        • et al.
        Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer.
        Br J Cancer. 2013; 109: 2665-2674
        • Kim R.
        • Coppola D.
        • Wang E.
        • Chang Y.D.
        • Kim Y.
        • Anaya D.
        • et al.
        Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma.
        Oncotarget. 2018; 9: 23366-23372
        • McGrail D.J.
        • Pilie P.G.
        • Rashid N.U.
        • Voorwerk L.
        • Slagter M.
        • Kok M.
        • et al.
        High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
        Ann Oncol. 2021; 32: 661-672
        • Dai S.
        • Liu T.
        • Liu X.Q.
        • Li X.Y.
        • Xu K.
        • Ren T.
        • et al.
        Identification of an immune-related signature predicting survival risk and immune microenvironment in gastric cancer.
        Front Cell Dev Biol. 2021; 9687473
        • Chen B.
        • Zheng B.
        • DeRan M.
        • Jarugumilli G.K.
        • Fu J.
        • Brooks Y.S.
        • et al.
        ZDHHC7-mediated S-palmitoylation of Scribble regulates cell polarity.
        Nat Chem Biol. 2016; 12: 686-693
        • Wu C.
        • Xu J.
        • Wang H.
        • Zhang J.
        • Zhong J.
        • Zou X.
        • et al.
        TMEM106a is a novel tumor suppressor in human renal cancer.
        Kidney Blood Press Res. 2017; 42: 853-864